Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment

Deidra M Ward; Aaliyah B Shodeinde; Nicholas A Peppas

doi:10.1002/adhm.202100350

Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment

Adv Healthc Mater. 2021 Jul;10(13):e2100350. doi: 10.1002/adhm.202100350. Epub 2021 May 11.

Authors

Deidra M Ward^{1

2}, Aaliyah B Shodeinde^{1

2}, Nicholas A Peppas^{1

2

3

4

5}

Affiliations

¹ McKetta Department of Chemical Engineering, 200 E. Dean Keeton St. Stop C0400, Austin, TX, 78712, USA.
² Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin, TX, 78712, USA.
³ Department of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton Street Stop C0800, Austin, TX, 78712, USA.
⁴ Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Ave. Stop A1900, Austin, TX, 78712, USA.
⁵ Department of Pediatrics and Department of Surgery and Perioperative Care, Dell Medical School, 1601 Trinity St., Bldg. B, Stop Z0800, Austin, TX, 78712, USA.

Abstract

Gene regulation using RNA interference (RNAi) therapy has been developed as one of the frontiers in cancer treatment. The ability to tailor the expression of genes by delivering synthetic oligonucleotides to tumor cells has transformed the way scientists think about treating cancer. However, its clinical application has been limited due to the need to deliver synthetic RNAi oligonucleotides efficiently and effectively to target cells. Advances in nanotechnology and biomaterials have begun to address the limitations to RNAi therapeutic delivery, increasing the likelihood of RNAi therapeutics for cancer treatment in clinical settings. Herein, innovations in the design of nanocarriers for the delivery of oligonucleotides for successful RNAi therapy are discussed.

Keywords: RNA interference; biomaterials; cancer; liposomal delivery; nanomedicine; polymeric nanocarriers.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Biocompatible Materials
Drug Carriers
Nanotechnology
Neoplasms* / genetics
Neoplasms* / therapy
RNA Interference
RNA, Small Interfering / genetics
RNAi Therapeutics*

Substances

Biocompatible Materials
Drug Carriers
RNA, Small Interfering

Grants and funding

R01 EB022025/EB/NIBIB NIH HHS/United States